Fesoterodine fumarate
CAS No. | 286930-03-8 | Cat. No. | BCP27699 |
Name | Fesoterodine fumarate | ||
Synonyms | Toviaz;SPM-907;SPM 907;SPM907; | ||
Formula | C30H41NO7 | M. Wt | 527.65 |
Description | Fesoterodine is an antimuscarinic drug developed to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012. Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder. | ||
Pathways | Neuro Signaling Pathway GPCR/G Protein | ||
Targets | mAChR |
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.